Insulin Types and Pharmacokinetics

• Insulin Receptor Signaling and Glucose Transport: Insulin binds to the insulin receptor tyrosine kinase on the cell surface of muscle, adipose, and hepatic cells, triggering autophosphorylation and recruitment of insulin receptor substrates (IRS-1 and IRS-2). This initiates phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling cascades. PI3K activation leads to AKT phosphorylation, which translocates glucose transporter type 4 (GLUT4) from intracellular vesicles to the cell membrane, enabling glucose uptake independent of blood glucose concentration. In muscle and adipose tissue, this accounts for approximately 80-90% of insulin-stimulated glucose disposal. The duration and magnitude of this effect depend directly on circulating insulin concentration and receptor occupancy, explaining why different insulin formulations produce distinct pharmacodynamic profiles despite identical molecular structures.

• Hepatic Glucose Metabolism and Lipogenesis: In the liver, insulin inhibits gluconeogenesis and glycogenolysis via dephosphorylation of key regulatory enzymes (phosphofructokinase-2, PEPCK) and simultaneously activates glycogen synthase, promoting hepatic glucose uptake and storage. Insulin suppresses the transcription factor FOXO1, which normally drives expression of gluconeogenic enzymes. Concurrently, insulin activates acetyl-CoA carboxylase and fatty acid synthase, promoting de novo lipogenesis and triglyceride synthesis. The hepatic metabolic switch from catabolic (fasting) to anabolic (fed) state is mediated by changes in AMP-dependent protein kinase (AMPK) activity and mTOR signaling. Intermediate-acting and long-acting insulins suppress hepatic glucose output continuously, preventing nocturnal and fasting hyperglycemia.

• Pharmacokinetic Determinants and Formulation Engineering: The pharmacokinetic behavior of insulin formulations is engineered through chemical modifications and excipient manipulation. Rapid-acting analogs (insulin lispro, aspart, glulisine) contain amino acid substitutions that disrupt dimer and hexamer formation, allowing rapid monomeric absorption from subcutaneous tissue with onset in 10-15 minutes and peak at 60-90 minutes. Regular (soluble) human insulin exists in hexameric form in pharmaceutical preparations, requiring slower dissociation before absorption, resulting in 30-minute onset and 2-4 hour peak. Intermediate-acting insulin (NPH) contains protamine, a positively charged protein that forms complexes with insulin, dramatically slowing absorption and extending action to 10-16 hours. Long-acting analogs use distinct mechanisms: insulin glargine (U-100 and U-300) precipitates at subcutaneous pH, creating a depot with peaking at 4-6 hours (U-100) or minimal peaking (U-300); insulin detemir undergoes albumin binding via a fatty acid chain, achieving relatively consistent action over 24 hours; insulin degludec forms multi-hexamers, providing the longest duration (>42 hours) and flattest profile. These pharmacokinetic differences result in clinically significant variations in time to action, peak effect, and duration of action, fundamentally affecting dosing strategies and hypoglycemia risk.

• Absorption Kinetics and Subcutaneous Depot Effects: Following subcutaneous injection, insulin undergoes lymphatic and capillary absorption dependent on injection site, local blood flow, and tissue binding. Abdominal wall injections are absorbed faster than thigh or arm injections due to higher subcutaneous blood flow. Insulin concentration gradients between depot and circulation drive absorption kinetics following first-order kinetics for most formulations. Intermediate and long-acting insulins create depots that provide sustained-release characteristics, smoothing out the insulin concentration curve and reducing glycemic variability compared to multiple daily injections of rapid-acting insulin alone. The subcutaneous route typically delays onset by 15-30 minutes compared to intravenous administration, explaining why subcutaneous insulin cannot treat acute hyperglycemia as rapidly as IV insulin infusion.

• Clearance and Hepatic Metabolism: Circulating insulin is cleared primarily via receptor-mediated endocytosis in the liver (60% of secreted insulin undergoes first-pass hepatic extraction) and kidney (filtered by glomerulus, reabsorbed by proximal tubule, then degraded). Hepatic clearance occurs through insulin receptor binding followed by lysosomal degradation via glutathione insulin transhydrogenase (GrB) and protease-mediated pathways. Renal clearance becomes significant in end-stage renal disease, necessitating dose reduction. Clearance rate is relatively constant across insulin formulations (approximately 200-300 mL/min), but this becomes clinically relevant only when exogenous insulin levels far exceed endogenous production. Insulin analogs have similar clearance mechanisms to human insulin, explaining their comparable half-lives when accounting for depot formation.

• Type 1 Diabetes Mellitus (Autoimmune Beta Cell Destruction): Autoimmune destruction of pancreatic beta cells via T-cell-mediated mechanisms (cytotoxic CD8+ T cells, helper CD4+ T cells) and B-cell autoantibodies (GAD65, IA-2, ZnT8, IAA) results in absolute insulin deficiency. Approximately 90% of new-onset type 1 diabetes in children and adolescents requires insulin immediately upon diagnosis. Genetic predisposition (HLA-DR3/DR4 alleles) combined with environmental triggers (viral infections, dietary antigens) initiates autoimmunity. These patients have zero endogenous insulin production within 5-10 years of diagnosis and are completely dependent on exogenous insulin. Type 1 diabetes accounts for 5-10% of all diabetes cases but represents the largest population requiring insulin therapy.

• Type 2 Diabetes Mellitus with Beta Cell Failure: Progressive pancreatic beta cell dysfunction develops over decades in type 2 diabetes, initially presenting with insulin resistance requiring high insulin concentrations to maintain normoglycemia. As beta cells progressively lose glucose-sensing capacity and secretory function (estimated 3-5% loss of beta cell function annually), endogenous insulin production becomes insufficient despite continuing insulin resistance. Approximately 50% of patients with type 2 diabetes require insulin within 10 years of diagnosis. Glucotoxicity (prolonged hyperglycemia), lipotoxicity (intramitochondrial fatty acid accumulation), and amyloid deposition in beta cells contribute to functional decline. Insulin therapy becomes necessary when oral agents and GLP-1 agonists fail to achieve glycemic targets.

• Secondary Causes of Insulin-Requiring Hyperglycemia: Pancreatitis (acute or chronic), hemochromatosis, cystic fibrosis-related diabetes, pancreatic cancer, post-pancreatectomy states, and chronic steroid use produce relative or absolute insulin deficiency requiring insulin replacement. Gestational diabetes mellitus requires insulin in 20-30% of affected pregnancies when dietary modification and metformin prove inadequate. Secondary causes account for <5% of insulin-requiring diabetes but are crucial to identify, as treatment of underlying condition may reduce insulin need.

• Acute Stress States and Decompensation: Infection, myocardial infarction, surgery, and severe illness produce transient insulin resistance and hyperglycemia requiring temporary insulin therapy even in previously insulin-independent patients. Hyperglycemic hyperosmolar hyperglycemic state (HHS) and diabetic ketoacidosis (DKA) are life-threatening acute complications requiring insulin as definitive therapy, though initially insulin infusion alone is insufficient without aggressive fluid resuscitation and electrolyte correction.

• Manifestations of Untreated Insulin Deficiency (Type 1 Diabetes Acute Presentation): Polyuria results from osmotic diuresis when plasma glucose exceeds the renal threshold (~180 mg/dL), causing glucose-induced aquaporin insufficiency and water loss. Polydipsia develops as compensatory thirst in response to hypersmolality and hypovolemia. Polyphagia reflects impaired nutrient uptake into insulin-dependent tissues despite elevated blood glucose—muscle and adipose cells are "glucose-blind" in insulin deficiency, triggering hypothalamic hunger signals despite abundant circulating glucose. Rapid weight loss (10-20 lbs over weeks) occurs from uncontrolled lipolysis and proteolysis as insulin-deficient cells shift to catabolic metabolism. Fatigue and malaise reflect metabolic derangement and declining cellular ATP production. Diabetic ketoacidosis (DKA) represents acute decompensation with Kussmaul respiration (deep, rapid breathing from metabolic acidosis), fruity-smelling breath (acetone), and altered mental status from cerebral edema. These acute presentations are the primary clinical indication for insulin initiation in type 1 diabetes.

• Manifestations of Inadequate Glycemic Control Despite Treatment (Chronic Hyperglycemia): Blurred vision results from osmotic changes in the lens and disruption of retinal function. Recurrent infections (urinary tract, skin) result from impaired neutrophil function and glucose-dependent bacterial growth. Neuropathic symptoms (numbness, tingling in feet) reflect sorbitol accumulation via aldose reductase pathway and myelin glycation. These develop insidiously over months to years and represent treatment failure or inadequate insulin dose/frequency.

• Manifestations of Excessive Insulin Therapy (Hypoglycemia): Autonomic symptoms include tremor, diaphoresis, palpitations, and anxiety from catecholamine surge triggered by rapid glucose decline. Neuroglycopenic symptoms include confusion, difficulty concentrating, behavioral changes, seizures, and loss of consciousness from impaired cerebral glucose metabolism. The threshold for symptom onset depends on individual glycemic variability—patients with longstanding diabetes may not perceive hypoglycemia until profound (hypoglycemia unawareness). Nocturnal hypoglycemia presents as night sweats, vivid nightmares, or morning hyperglycemia (from counterregulatory hormone release). The clinical presentation of hypoglycemia varies dramatically between individuals and even in the same person depending on glucose nadir, rate of decline, and recent glycemic history.

• Physical Examination Findings: Patients on insulin therapy show lipodystrophy at injection sites (lipoatrophy from repeated injections causing subcutaneous fat loss, or lipohypertrophy from growth factor stimulation). Necrobiosis lipoidica appears as shiny, reddish-brown patches typically on the anterior tibia in diabetic patients. Acanthosis nigricans (velvety hyperpigmentation of neck/axillae) indicates underlying insulin resistance. Diabetic foot ulcers result from combination of neuropathy and vascular insufficiency. Periorbital edema and macular edema may develop with initiation of insulin in previously uncontrolled diabetes due to rapid glucose decline and fluid retention. Signs of peripheral neuropathy (diminished vibration sense, absent ankle reflexes) indicate chronic hyperglycemia.

• Clinical Variants and Presentations: Brittle diabetes describes unpredictable, wide glycemic fluctuations requiring frequent insulin adjustments; results from increased insulin sensitivity, impaired counterregulation, or psychological factors. Dawn phenomenon presents as fasting hyperglycemia (elevated 6-8 AM glucose) despite adequate bedtime insulin, driven by growth hormone and cortisol surge. Somogyi phenomenon produces fasting hyperglycemia from nocturnal hypoglycemia triggering excessive counterregulation. Insulin resistance manifests as requirement for very high insulin doses (>2-3 units/kg/day) with poor glycemic control, seen in obesity, acanthosis nigricans, and autoimmune insulin resistance (rare).

• Clinical Diagnosis of Type 1 Diabetes (Insulin Requirement): The diagnosis of type 1 diabetes requiring insulin is confirmed by presence of fasting glucose ≥126 mg/dL (≥7.0 mmol/L), random glucose ≥200 mg/dL (≥11.1 mmol/L) with symptoms, or 2-hour glucose ≥200 mg/dL on oral glucose tolerance test. Supporting autoimmune markers include positive GAD65 antibodies, IA-2 antibodies, ZnT8 antibodies, or ICA (islet cell antibodies); at least one autoantibody is positive in 85-90% of type 1 diabetes cases. C-peptide level <0.6 ng/mL (measured 2 hours after glucose challenge) indicates severe beta cell dysfunction and absolute insulin requirement. Absence of obesity and presence of acute presentation strongly suggest type 1 diabetes requiring insulin from diagnosis.

• Laboratory Tests Guiding Insulin Therapy: Hemoglobin A1c (glycated hemoglobin reflecting average glucose over 2-3 months) is the primary marker for insulin dose titration. Target A1c varies by patient age and comorbidities: 7.0-7.5% for most non-pregnant adults, 8.0% for elderly patients with limited life expectancy, 6.5% for pregnant patients. Fasting glucose and bedtime glucose guide basal insulin dose adjustment; elevated fasting glucose (>150 mg/dL despite adequate bedtime insulin) requires increased long-acting insulin. Preprandial glucose (before meals) guides bolus (meal-time) insulin adjustments. 2-hour postprandial glucose and continuous glucose monitoring (CGM) data identify postprandial hyperglycemia requiring increased rapid-acting insulin doses. Serum creatinine and estimated glomerular filtration rate (eGFR) are essential as renal dysfunction impairs insulin clearance—eGFR <30 mL/min/1.73m² requires 20-50% insulin dose reduction. Urine or serum ketones are checked during acute illness or suspected DKA; presence indicates need for IV insulin infusion.

• Diagnostic Markers of Insulin Deficiency vs Resistance: C-peptide level distinguishes absolute insulin deficiency (type 1 diabetes, C-peptide <0.1 ng/mL) from relative deficiency (type 2 diabetes, variable C-peptide). Insulin level during fasting or glucose challenge (>12 μU/mL during fasting or >60 μU/mL at 2 hours of OGTT) indicates insulin resistance. HOMA-IR score (Homeostasis Model Assessment for Insulin Resistance) = [fasting insulin (μU/mL) × fasting glucose (mg/dL)] / 405; HOMA-IR >2.0 indicates insulin resistance, relevant when determining insulin requirement in type 2 diabetes.

• Diagnostic Imaging: Imaging is not required for insulin therapy diagnosis. However, abdominal ultrasound or CT may reveal pancreatic atrophy in chronic pancreatitis, pancreatic cancer, or hemochromatosis when secondary causes are suspected. Retinal imaging documents diabetic retinopathy at baseline in insulin-requiring diabetes.

• Diagnostic Criteria for Insulin Requirement: While no single test defines insulin requirement, clinical thresholds guide initiation: (1) Type 1 diabetes—any patient with autoimmune diabetes requires insulin; (2) Type 2 diabetes—insulin indicated when A1c remains >7.5% despite maximal oral agents and

Formulation facts examiners repeat

• Regular insulin is the standard IV insulin: hexamer dissociation is irrelevant when insulin enters the blood directly, so IV regular insulin is the preferred (and cheapest) agent for DKA/HHS infusions per the ADA Standards of Care, and for insulin-plus-dextrose treatment of hyperkalemia (ACLS/nephrology practice). Rapid-acting analogs can also be given IV, but a stem describing subcutaneous rapid-acting insulin for severe DKA is the intended wrong answer.
• Rapid-acting analogs (lispro, aspart, glulisine) are dosed at or just before the meal; regular insulin must be given roughly a half-hour before eating. Mismatched injection–meal timing is the classic cause of early postprandial hyperglycemia followed by late hypoglycemia.
• Among basal insulins, NPH is the one with a clinically prominent peak (roughly 4–10 hours after injection), making bedtime NPH the formulation most associated with nocturnal hypoglycemia. Glargine U-300 and degludec are essentially flat; glargine U-100 and detemir have a blunted, clinically minor peak (detemir often lasting <24 h at lower doses). Prandial insulins peak by design — regular at ~2–4 h, rapid-acting at ~60–90 min.
• Do not mix long-acting analogs in a syringe with other insulins — glargine's acidic pH depends on subcutaneous precipitation. NPH and regular can be mixed (draw clear before cloudy).

The association most often tested

• Insulin drives K⁺ intracellularly via Na⁺/K⁺-ATPase, independent of glucose uptake — hence its use in hyperkalemia, and hence the rule that insulin is withheld in DKA until potassium is repleted. The 2024 ADA/EASD hyperglycemic crises consensus uses a threshold of serum K⁺ <3.5 mEq/L; older sources and many question banks still use <3.3 mEq/L.

Distractors to avoid

• Fasting hyperglycemia: check a 3 AM glucose as the next step. Low at 3 AM suggests Somogyi rebound (reduce or move basal); normal-to-high at 3 AM indicates dawn phenomenon from GH/cortisol surge (increase or shift basal later). Somogyi is contested in modern CGM data but remains testable.
• Renal impairment prolongs insulin action — reduce, do not increase, the dose. Insulin remains usable at any eGFR, unlike metformin.
• Non-selective beta blockers blunt adrenergic warning symptoms but spare diaphoresis; suspect this in a diabetic with unrecognized hypoglycemia.
• Treat conscious hypoglycemia with ~15 g oral fast carbohydrate and recheck in 15 minutes; if obtunded, give IM/intranasal glucagon or IV dextrose (ADA). Insulin causes weight gain, not loss — do not choose it as a weight-neutral agent.